Potassium clavulanate (CAS 61177-45-5) is a critical raw material in beta-lactam formulations, where stability, purity and potency require careful control. Its sensitivity to moisture, temperature and pH makes material selection, analytical control, storage and packaging key factors in reducing risk during development, manufacturing and quality evaluation.
This guide summarizes the main points that QA, development, production and regulatory affairs teams should consider when assessing potassium clavulanate: critical tests, related substances, stability conditions, moisture control, storage and technical documentation.
What potassium clavulanate is and why strict control matters
Potassium clavulanate is the potassium salt of clavulanic acid. In beta-lactam formulations, it is commonly assessed for its role as a beta-lactamase inhibitor, particularly in combinations with antibiotics such as amoxicillin.
From a quality perspective, its value depends on maintaining chemical integrity and potency across the full chain: API receipt, manufacturing, packaging, storage, distribution and final product use.
For this reason, potassium clavulanate requires a well-defined specification, suitable analytical methods and a risk-based control approach. Assessment should consider assay, identity, water, related substances, specific impurities and storage conditions.
Main stability risks
Potassium clavulanate stability may be affected by several factors. The most relevant are moisture, temperature, pH and exposure time during processing or storage.
- Moisture: may promote degradation and an increase in related substances.
- Temperature: can accelerate potency loss and formation of degradation products.
- pH: solutions or reconstituted mixtures require careful control within the range defined by the formulation.
- Packaging: protection from moisture and temperature depends on the selected packaging system.
- In-use period after reconstitution: should be defined through stability data and the applicable final product labelling.
For moisture-sensitive projects or products intended for warm climates, it is especially important to assess high-barrier packaging, desiccants and water activity control of critical excipients.
Stability and ICH framework
The stability design should be aligned with the ICH Q1A(R2) approach, considering long-term, intermediate and accelerated conditions depending on the target market, climatic zone and final product. For potassium clavulanate, the plan should pay particular attention to trends in potency, water and related substances.
| Study type | Indicative condition | Objective | Points of attention for clavulanate |
|---|---|---|---|
| Long-term | 25 °C / 60 % RH or applicable condition | Confirm real stability trend | Monitor assay, water, related substances and final packaging behaviour. |
| Intermediate | 30 °C / 65 % RH, when applicable | Assess sensitivity to moderate conditions | Useful if accelerated data raises questions or for demanding climatic markets. |
| Accelerated | 40 °C / 75 % RH | Assess robustness of the system | Monitor degradation, specific impurities and suitability of packaging/desiccant. |
In addition to initial studies, an ongoing stability program can help detect trends and anticipate deviations during the commercial life of the product.
API quality control
Quality control of potassium clavulanate should be based on the applicable monograph, regulatory requirements of the market and specific risks linked to the manufacturing process. The most relevant tests often include:
- Identification using a suitable technique, such as IR, UV or chromatography.
- Assay by validated method, commonly HPLC.
- Related substances and specific impurities according to monograph or agreed specification.
- Water content, for example by Karl Fischer.
- Solution pH, when applicable.
- Residual solvents or process-related impurities, when relevant.
- Metals or elemental impurities, when applicable according to risk assessment.
For quality and regulatory affairs teams, the analytical result is not the only factor. Batch traceability, documentary consistency, CoA, SDS, technical specification and, where available, additional information such as CEP/COS or pharmacopoeial support documentation are also important.
Impurities and related substances
Monitoring related substances is one of the most important elements in potassium clavulanate assessment. Degradation may be influenced by moisture, temperature, pH and processing conditions, so the method must be able to detect relevant changes during manufacturing and stability.
A practical approach is to define a prioritized impurity panel based on the applicable monograph, the manufacturer history, the intended use of the material and the requirements of the final product. This panel can feed periodic trending reviews and help detect variations before they create regulatory or quality impact.
Finished product control and combinations with amoxicillin
When potassium clavulanate is part of a combination with amoxicillin or another beta-lactam, control should consider both active ingredients and their behaviour within the final matrix.
- Assay of both active ingredients using a stability-indicating method.
- Control of related substances for both amoxicillin and clavulanate.
- Dose uniformity, when applicable.
- Dissolution or release profile, where relevant to the product.
- pH, appearance and organoleptic characteristics in reconstituted suspensions.
- In-use period after reconstitution, defined by product-specific stability data and applicable labelling.
- Excipient compatibility and water activity within the matrix.
This approach helps reduce the risk of potency loss, impurity increase and deviations during the shelf life of the product.
Formulation and packaging recommendations
Potassium clavulanate stability is best protected when formulation development, process design and packaging are managed together. Practical points to consider include:
- Process: limit exposure to moisture and unnecessary thermal steps.
- Excipients: prioritize low-hygroscopicity materials and assess water activity.
- Packaging: consider high-barrier systems, such as alu-alu or HDPE with desiccant, depending on the product.
- Desiccant: size capacity according to shelf life, headspace volume and expected conditions.
- Storage: maintain dry conditions and controlled temperature according to specification.
- Labelling: define clear instructions for storage, reconstitution and in-use period when applicable.
Safety, handling and storage
Potassium clavulanate should always be handled according to the current supplier SDS and the laboratory or plant risk assessment. As a general recommendation, exposure to moisture, dust, heat and ignition sources should be minimized when indicated by the SDS.
To maintain material quality, use tightly closed containers, dry conditions, controlled temperature and appropriate handling to avoid contamination, moisture uptake or degradation during use.
How DC Fine Chemicals can support
At DC Fine Chemicals, our approach is to help customers assess raw materials with a technical and documentary perspective. For potassium clavulanate, this may include support in reviewing specifications, available quality documentation, CoA, SDS, regulatory information and technical data linked to the product, depending on project scope and availability.
For research, microbiology or culture media applications, DC Fine Chemicals offers potassium clavulanate for laboratory use. The suitability of the material for a specific application must be assessed and approved by the customer according to its own technical, regulatory and quality requirements.
Operational checklist for potassium clavulanate assessment
- Define a specification aligned with the monograph, intended use and process risks.
- Confirm identity, assay, water and related substances.
- Review process-related impurities and available manufacturer documentation.
- Assess sensitivity to moisture, temperature and pH.
- Select packaging and desiccant according to stability risk.
- Validate stability-indicating methods for the final product.
- Define storage, transport and in-use conditions after reconstitution when applicable.
- Document acceptance criteria and trending follow-up.
Frequently asked questions
Why is potassium clavulanate stability-sensitive?
Because it may degrade due to moisture, temperature, pH and processing conditions. This is why it requires analytical control, appropriate storage and packaging that reduces moisture exposure.
Which tests are most relevant for its control?
Common tests include identity, assay, related substances, water, solution pH when applicable, and specific process-related or monograph impurities.
What should be reviewed in combinations with amoxicillin?
Assay and impurities of both active ingredients, excipient compatibility, product behaviour during stability and in-use period after reconstitution when applicable.
Which documents may support audits or qualification?
Batch CoA, technical specification, SDS, regulatory information, manufacturer traceability and pharmacopoeial or supporting documentation when available.
Can DC Fine Chemicals support the technical assessment?
Yes. Our team can review the technical and documentary requirements of the project and confirm the available information to support the customer’s internal assessment.
If you need to assess potassium clavulanate for a technical, research or culture media project, contact our team to review the specification, available documentation and quality requirements.
The information provided by DC Fine Chemicals is intended to support the technical, documentary and regulatory assessment of each raw material. The suitability, qualification, validation and approval of the product for a specific final application must be determined exclusively by the customer.